Actavis Group, a generic pharmaceuticals company, has gained FDA approval for Ropinirole extended-release tablets, 2mg, 4mg, 6mg, 8mg and 12mg.
The company has started distribution of the generic version of GlaxoSmithKline's Requip XL.
Actavis CEO Doug Boothe said, "The launch of Ropinirole Extended-Release Tablets showcases Actavis' commitment in bringing new products to market to benefit both patients and payors. We are proud to play a part in lowering healthcare costs through the introduction of quality generic products."
According to IMS Health, Requip XL, 2mg, 4mg, 6mg, 8mg and 12mg, had US sales of approximately $59.4m for the 12 months ending 31 December 2011.